ECI Biotech Receives $2M in Series D Equity Placement

March 28, 2007 — ECI Biotech is please to announce that it has secured an additional $2M in equity financing from private investment sources. The capital will be used to develop ECI’s first product, a point-of-care rapid diagnostic for wound infection, based upon ECI’s patented ExpressDetect® technology platform. The product is intended to provide an indication of wound infection within 15 minutes and will serve the growing $1.2B advanced wound care market.

Back to news